Alto Neuroscience reveals positive ALTO-101 Phase I trial results
Alto Neuroscience has reported positive results from its Phase I clinical trial of the PDE4 inhibitor, ALTO-101, for treating cognitive…
Alto Neuroscience has reported positive results from its Phase I clinical trial of the PDE4 inhibitor, ALTO-101, for treating cognitive…
Response Pharmaceuticals announced that the Phase Ib clinical trial yielded positive results for RDX-002, a novel treatment aimed at preventing…
Neurocrine Biosciences has announced positive topline data from its Phase II SAVITRI study, evaluating the efficacy and safety of NBI-1065845…
South Korea-based Hanmi Pharmaceutical has signed a clinical trial collaboration and supply agreement with MSD, a tradename of Merck &…
Biotechnology company Ocugen has completed dosing in the second cohort of its Phase I/II ArMaDa clinical trial of modifier gene therapy…
ACTG has launched A5374, a Phase I/IIa clinical trial to evaluate the safety, tolerability, and antiviral effect of a combination…
The US Food and Drug Administration (FDA) has granted approval for GenFleet Therapeutics’ Phase III clinical trial of GFH925, a…
Kintor Pharma has announced that its GT20029 Phase II trial in China has met the primary endpoint, showing significant results…
Vistagen has enrolled the first patient in the PALISADE-3 Phase III clinical trial of fasedienol (PH94B) being developed for social…
The Data Safety and Monitoring Board (DSMB) has granted approval for progression to the medium dose in Ocugen’s OCU410ST clinical…